Unfortunately, other immunosuppressant drugs routinely exploited in the management of RA and JIA, such as anti-IL6 (tocilizumab, sarilumab) and anti-IL17 agents, lack of sufficient evidence to be integrated into the pharmacological armamentarium of MS; conversely, IL-1 antagonists and abatacept were trialled in MS with poor results [106]. This evidence concerns the gene IL17A and myeloid sarcoma.